Chikungunya Vaccine Ixchiq Linked to Aseptic Meningitis Risk: EMA and FDA Updates
European, and U.S. Health authorities are advising healthcare providers to be aware of a potential risk of aseptic meningitis following vaccination with Ixchiq, a live attenuated chikungunya vaccine developed by Valneva. While the risk is considered known, recent data prompted updates to the vaccine’s product information to better inform medical professionals and patients.
What is Ixchiq?
Ixchiq is a vaccine designed to protect against chikungunya virus, a mosquito-borne illness that can cause fever and severe joint pain. The vaccine contains a live, weakened version of the virus, which may cause symptoms similar to those experienced during a chikungunya infection FDA.
Aseptic Meningitis: What You Need to Know
Aseptic meningitis is an inflammation of the membranes surrounding the brain and spinal cord that is not caused by bacteria. Symptoms can include headache, fever, and stiff neck. The European Medicines Agency’s (EMA) pharmacovigilance committee (PRAC) has been reviewing reports of this condition following Ixchiq vaccination The Pharma Letter.
Regulatory Updates and Recommendations
The EMA’s PRAC has completed its review of the safety signal and recommended an update to Ixchiq’s product information. This update reflects the most recent evidence related to the known risk of aseptic meningitis EMA. Similarly, the U.S. Food and Drug Administration (FDA) is monitoring the safety of Ixchiq and provides updates as new information becomes available FDA.
What Does This Mean for Patients?
Individuals who receive the Ixchiq vaccine should be aware of the potential for aseptic meningitis and report any concerning symptoms to their healthcare provider. The EMA and FDA emphasize that the benefits of vaccination should be weighed against the potential risks.
Key Takeaways
- Ixchiq, a chikungunya vaccine, has been linked to a known risk of aseptic meningitis.
- European and U.S. Regulatory agencies are updating product information to reflect this risk.
- Patients should be aware of the symptoms of aseptic meningitis and seek medical attention if they develop after vaccination.
The post Ixchiq Vaccine & Meningitis Risk: European Safety Update appeared first on Archynewsy.